Martinello M, Solomon SS, Terrault NA, et al. Hepatitis C. Lancet. 2023;402:1085–96.

Article  PubMed  Google Scholar 

Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol. 2021;74:952–63.

Article  PubMed  Google Scholar 

Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–47.

Article  PubMed  Google Scholar 

Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection. N Engl J Med. 2021;384:1038–52.

Article  CAS  PubMed  Google Scholar 

Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212–24.

Article  CAS  PubMed  Google Scholar 

Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23:521–30.

Article  PubMed  PubMed Central  Google Scholar 

Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691–705.

Article  CAS  PubMed  Google Scholar 

Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71:156–62.

Article  PubMed  Google Scholar 

Dyal HK, Aguilar M, Bhuket T, et al. Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients: a systematic review. Dig Dis Sci. 2015;60:2813–24.

Article  CAS  PubMed  Google Scholar 

Dyal HK, Aguilar M, Bartos G, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review. Dig Dis Sci. 2016;61:636–45.

Article  CAS  PubMed  Google Scholar 

Peleg N, Issachar A, Sneh Arbib O, et al. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. J Viral Hepat. 2019;26:1257–65.

Article  CAS  PubMed  Google Scholar 

van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66:485–93.

Article  PubMed  Google Scholar 

Benhammou JN, Moon AM, Pisegna JR, et al. Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C. Dig Dis Sci. 2021;66:2394–406.

Article  CAS  PubMed  Google Scholar 

Degasperi E, D’Ambrosio R, Iavarone M, et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol. 2019;17:1183-91.e7.

Article  CAS  PubMed  Google Scholar 

Wiese M, Fischer J, Löbermann M, et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology. 2014;59:49–57.

Article  CAS  PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;76:1542–56.

Article  Google Scholar 

Fouad Y, Lazarus JV, Negro F, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment Pharmacol Ther. 2021;53:1080–9.

Article  PubMed  Google Scholar 

Castéra L, Hézode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut. 2004;53:420–4.

Article  PubMed  PubMed Central  Google Scholar 

Shimizu K, Soroida Y, Sato M, et al. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter. Sci Rep. 2018;8:7845.

Article  PubMed  PubMed Central  Google Scholar 

Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2018;47:1012–22.

Article  CAS  PubMed  Google Scholar 

Kobayashi N, Iijima H, Tada T, et al. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol. 2018;30:546–51.

Article  PubMed  Google Scholar 

Niu B, Zang W, Zhou H, et al. Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment. BMC Gastroenterol. 2023;23:102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chuaypen N, Siripongsakun S, Hiranrat P, et al. Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: role of metabolic derangement and host genetic variants. PLoS ONE. 2022;17: e0269641.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawagishi N, Suda G, Nakamura A, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS ONE. 2018;13: e0209615.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tokuchi Y, Suda G, Kawagishi N, et al. Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight. Hepatol Res. 2023;53:595–606.

Article  CAS  PubMed  Google Scholar 

Trifan A, Stratina E, Rotaru A, et al. Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis C infection treated with direct-acting antivirals therapy who achieved sustained virological response. Diagnostics (Basel). 2022;12:702.

Article  CAS  PubMed  Google Scholar 

Rout G, Nayak B, Patel AH, et al. Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography. J Clin Exp Hepatol. 2019;9:207–14.

Article  PubMed  Google Scholar 

Graf C, Welzel T, Bogdanou D, et al. Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis. J Clin Med. 2020;9:2702.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022–30.

Article  PubMed  Google Scholar 

Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828–35.

PubMed  Google Scholar 

Wong VW, Petta S, Hiriart JB, et al. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. J Hepatol. 2017;67:577–84.

Article  PubMed  Google Scholar 

Liu CH, Liang CC, Liu CJ, et al. Comparison of Abbott RealTime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping. J Clin Microbiol. 2015;53:1754–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.

Article  CAS  PubMed  Google Scholar 

Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–47.

Article  PubMed  Google Scholar 

Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.

Article  CAS  PubMed  Google Scholar 

Ribaldone DG, Sacco M, Saracco GM. The effect of viral clearance achieved by direct-acting antiviral agents on hepatitis C virus positive patients with type 2 diabetes mellitus: a word of caution after the initial enthusiasm. J Clin Med. 2020;9:563.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciancio A, Ribaldone DG, Dotta A, et al. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. Liver Int. 2021;41:276–87.

Article  CAS  PubMed  Google Scholar